Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19

Preface

(2020) Dipak Panigrahy et al.   CANCER AND METASTASIS REVIEWS

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

(2020) Haibo Zhang et al.   INTENSIVE CARE MEDICINE

A hypothesis for pathobiology and treatment of COVID‐19 : The centrality of ACE1 / ACE2 imbalance

(2020) Krishna Sriram et al.   BRITISH JOURNAL OF PHARMACOLOGY

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

(2020) Evangelos J. Giamarellos-Bourboulis et al.   Cell Host & Microbe

The p38 Pathway: From Biology to Cancer Therapy

(2020) Adrián Martínez-Limón et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

(2020) Betsy J. Barnes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly

(2020) Roel P. H. De Maeyer et al.   NATURE IMMUNOLOGY

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cytokine release syndrome in severe COVID-19

(2020) John B. Moore et al.   SCIENCE

Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

(2020) Laure Wynants et al.   BMJ-British Medical Journal

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

(2020) Mehdi Bouhaddou et al.   CELL

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

(2020) Mark Roschewski et al.   Science Immunology

Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19

(2020) Jun Wang et al.   Frontiers in Immunology

Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome

(2019) I-Yin Chen et al.   Frontiers in Microbiology

AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFαwith Minimal Systemic Exposure

(2018) Rikard Pehrson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial

(2018) Marie Fisk et al.   PLoS One

The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial

(2018) Naimish Patel et al.   International Journal of Chronic Obstructive Pulmonary Disease

Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD

(2017) Steven Pascoe et al.   RESPIRATORY MEDICINE

Mitogen-activated protein kinases (MAPKs) regulate IL-6 over-production during concomitant influenza virus and Staphylococcus aureus infection

(2017) Carolin Klemm et al.   Scientific Reports

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

(2016) Rudragouda Channappanavar et al.   Cell Host & Microbe

Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease

(2016) P. S. Pillai et al.   SCIENCE

Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2

(2015) Dauren Alimbetov et al.   BIOGERONTOLOGY

Angiotensin-Converting Enzyme 2 Attenuates Bleomycin-Induced Lung Fibrosis in Mice

(2015) Lifang Wang et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

(2015) Jason D. Christie et al.   CRITICAL CARE MEDICINE

Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease

(2014) Marie Fisk et al.   American Journal of Cardiovascular Drugs

Age-related activation of MKK/p38/NF-κB signaling pathway in lung: From mouse to human

(2014) Xiaoxia Ren et al.   EXPERIMENTAL GERONTOLOGY

Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Axis Protects against Lung Fibrosis by Inhibiting the MAPK/NF-κB Pathway

(2013) Ying Meng et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Inhibition of p38 Mitogen-activated Protein Kinase Impairs Influenza Virus-induced Primary and Secondary Host Gene Responses and Protects Mice from Lethal H5N1 Infection

(2013) Yvonne Börgeling et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial

(2013) William MacNee et al.   THORAX

Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial

(2013) Henrik Watz et al.   Lancet Respiratory Medicine

Impaired secretion of interferons by dendritic cells from aged subjects to influenza

(2012) Sangeetha Prakash et al.   AGE

Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia

(2011) Joseph Cheriyan et al.   CIRCULATION

p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype

(2011) Adam Freund et al.   EMBO JOURNAL

Impaired Interferon Signaling in Dendritic Cells From Older Donors Infected In Vitro With West Nile Virus

(2011) Feng Qian et al.   JOURNAL OF INFECTIOUS DISEASES

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis

(2011) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

(2010) Jean-Philippe Coppé et al.   Annual Review of Pathology-Mechanisms of Disease

Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63

(2009) I. Glowacka et al.   JOURNAL OF VIROLOGY

Angiotensin II Up-Regulates Angiotensin I-Converting Enzyme (ACE), but Down-Regulates ACE2 via the AT1-ERK/p38 MAP Kinase Pathway

(2008) Vijay Koka et al.   AMERICAN JOURNAL OF PATHOLOGY